ANGLE’s H121 results confirm progress of its proprietary Parsortix cancer diagnostic platform across multiple fronts. Whilst attention inevitably focusses on the expected upcoming FDA approval for use in metastatic breast cancer, important progress has been achieved with developing the ovarian cancer LDT (Laboratory Developed Test). UK and US clinical laboratories, created ahead of schedule, are anticipated to receive certification by year-end. This will drive nearer term revenues from pharma services, demonstrate the clinical value, and validate the proposition for larger commercial labs. Collectively these efforts will help shape Parsortix’s positioning in the emerging, and dynamic, liquid biopsy market. We value ANGLE at £581m ($755m), 248p/share.
